Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kirin Pharma Exec Tamao Watanabe On U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Painstaking communication efforts, including putting plans in writing to overcome a language gap, are keys to Kirin’s partnership with Argos.

You may also be interested in...

Argos Therapeutics CEO Jeffrey Abbey on U.S. Biotech-Japan Pharma Collaborations: An Interview With PharmAsia News (Part 1 Of 2)

North Carolina-based Argos Therapeutics CEO Jeffrey Abbey recently spoke with PharmAsia News about the unique opportunities and challenges for U.S. biotechs looking to collaborate with Japanese pharma companies. Abbey discussed his experience partnering with Kirin Pharma and why it is a good time for U.S. biotechs to look for Japanese partners.

Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus

Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry

Japan’s 2014 Drug Price Reforms Extend Price Premium Program

The Japanese government has decided to revise its drug pricing policies starting in April 2014. Changes include extending a price premium program for two more years, bundling the pricing of similar generic drugs, and reduced pricing on long-listed drugs.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts